免疫检查点抑制剂Immune Checkpoint inhibitor

lb2383 · 发表于 2014-2-6 01:22:50

The Role of Anti-PD-L1 Immunotherapy in Cancer
http://www.onclive.com/web-exclu ... therapy-in-cancer/1

yuds · 发表于 2014-2-7 13:46:38

前世今生发表于 2014-1-5 00:29
贵的不是一般呀，求大神们赶紧出YL吧！

这些药好像都是注射药，就是有yl,草根们也是很难实施的，只有寄希望印度能出代用品。

mindfury · 发表于 2014-2-14 08:52:43

http://blog.sina.com.cn/s/blog_af34cba10101jfq5.html

2月12日，Pierre Fabre与Aurigene达成合作协议，共同开发肽类PD-1拮抗剂AUNP-12。AUNP-12是目前唯一一个针对PD-1信号的肽类药物，目前已完成临床前研究，能够抑制肿瘤的生长和转移，未发现明显的毒性。

Anti-PD-1/PDL-1这块蛋糕太大了，印度厂Aurigene也想来分一杯羹，不过据历史数据多肽类癌症药物研发失败率极高，祝它好运吧。

costa_na · 发表于 2014-3-4 02:23:20

Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer

Abstract | Previously, clinical approaches to using the immune system against cancer focused on vaccines that intended to specifically initiate or amplify a host response against evolving tumours. Although vaccine approaches have had some clinical success, most cancer vaccines fail to induce objective tumour shrinkage in patients. More-recent approaches have centred on a series of molecules known as immune checkpoints—whose natural function is to restrain or dampen a potentially over-exuberant response. Blocking immune checkpoint molecules with monoclonal antibodies has emerged as a viable clinical strategy that mediates tumour shrinkage in several cancer types. In addition to being part of the current treatment armamentarium for metastatic melanoma, immune checkpoint blockade is currently undergoing phase III testing in several cancer types.

nrclinonc.2013.208.pdf (325.1 KB, 下载次数: 83)

做凡人 · 发表于 2014-3-25 11:55:58

如果有移植的病人，用这个会不会也增加排斥呢？

做凡人 · 发表于 2014-3-25 11:56:18

costa_na 发表于 2014-3-4 02:23
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer

Abstract | Prev ...

如果有移植的病人，用这个会不会也增加排斥呢？

elexujx · 发表于 2014-4-10 18:02:10

各位专家显身手, 各位菜鸟学习忙.

老马 · 发表于 2014-6-11 17:14:55

2 prominent themes at ASCO 2014
http://www.orf-blog.com/2-prominent-themes-at-asco-2014/#more-653

presario410 · 发表于 2014-8-28 10:25:17

作为色素瘤的治疗药物，最快可能在10月28号被FDA认证.

"An application for US Food and Drug Administration approval for pembrolizumab use in patients with advanced melanoma previously treated with ipilimumab has been granted priority review by the agency, with an action date of October 28."

http://www.medscape.com/viewarticle/828738